Outcomes

What were the main findings from the study?

MICARDIS^® 40 mg or 80 mg plus HCTZ provided significantly greater reductions in DBP and SBP in the last 6 hours of the dosing interval than losartan 50 mg plus HCTZ.²

MICARDIS^® 40 mg or 80 mg plus HCTZ significantly reduced 24-hour mean DBP and SBP compared with losartan plus HCTZ.²

During the risky early morning hours, MICARDIS^® may be more effective than losartan in attenuating the morning surge in blood pressure. In turn, this may reduce the risk of CV events^.2

Both MICARDIS^® high- and low-dose groups achieved significantly greater reductions in DBP and SBP than losartan in the last 6 hours of the dosing interval  

Reductions in mean DBP were greater with both doses of MICARDIS^® than with losartan during the 24-hour period

More patients in the MICARDIS^® group achieved a blood pressure response compared with the losartan group This reached significance for patients in the MICARDIS^® 80 mg group

References